SCHEMBL17401124

SCHEMBL17401124

Fc1ccc(-c2c[nH]c([C@@H]3CCCN3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.37
MKNK1 Q9BUB5 2/20 0.36
MKNK2 Q9HBH9 1/20 0.36
PARP1 P09874 4/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
MAPK13 O15264 2/20 0.34
RAF1 P04049 2/20 0.34
MAPK9 P45984 2/20 0.34
MAPK12 P53778 2/20 0.34
MAPK11 Q15759 2/20 0.34
MAPK14 Q16539 2/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18498321 1.00 KCNH2 (0.37) KCNH2MKNK1MKNK2PARP1SCN10A
SCHEMBL6166898 0.96 PARP1 (0.36) KCNH2MKNK1MKNK2PARP1CHRNB2
SCHEMBL10177443 0.93 CHRNB2 (0.39) MKNK1PARP1SCN10ACHRNB2CHRNA7
SCHEMBL15105935 0.91 CHRNB2 (0.38) MKNK1PARP1SCN10ACHRNB2CHRNA7
SCHEMBL882749 0.91 CHRNB2 (0.38) MKNK1PARP1SCN10ACHRNB2CHRNA7
SCHEMBL883089 0.91 CHRNB2 (0.38) MKNK1PARP1SCN10ACHRNB2CHRNA7
SCHEMBL2368242 0.87 PARP1 (0.34) KCNH2MKNK1PARP1CHRNB2CHRNA7
SCHEMBL12682632 0.86 CYP1A2 (0.40) MKNK1PARP1SCN10ACHRNB2CHRNA7
SCHEMBL12682669 0.86 MKNK1 (0.40) MKNK1PARP1SCN10ACHRNB2CHRNA7
SCHEMBL2683531 0.86 CDC7 (0.40) MKNK1PARP1SCN10ACHRNB2CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9868758-B2 Betulinic proline imidazole derivatives as HIV inhibitors HETERO LABS LIMITED (IN) 2018-01-16 US disclosed
US-9868758-B2 Betulinic proline imidazole derivatives as HIV inhibitors HETERO LABS LIMITED (IN) 2018-01-16 US disclosed
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2017-05-11 US disclosed
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2017-05-11 US disclosed
WO-2017025901-A1 NOVEL C28-ANALOGUES WITH C3-MODIFICATIONS OF TRITERPENE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-02-16 WO disclosed
WO-2016001820-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, IMPA1 KCNH2 4678/4885MKNK1 787/4885MKNK2 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.